MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
OpGen Retained Earnings 2011-2026 | OPGN
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -294 M | -305 M | -273 M | -236 M | -201 M | -175 M | -162 M | -149 M | -133 M | -114 M | -96.8 M | -91.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -91.1 M | -305 M | -186 M |
Quarterly Retained Earnings OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -291 M | -290 M | -294 M | -294 M | -298 M | -307 M | - | -305 M | -288 M | -284 M | -279 M | -273 M | -262 M | -248 M | -242 M | -236 M | -229 M | -223 M | -216 M | -201 M | -201 M | -201 M | -201 M | -175 M | -175 M | -175 M | -175 M | -162 M | -162 M | -162 M | -162 M | -149 M | -149 M | -149 M | -149 M | -133 M | -133 M | -133 M | -133 M | -114 M | -114 M | -114 M | -114 M | -96.8 M | -96.8 M | -96.8 M | -96.8 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -96.8 M | -307 M | -195 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 116.36 | 0.7 % | $ 35.4 B |  USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 128.32 | 0.34 % | $ 20.4 B | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.68 | 0.6 % | $ 2.23 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 84.5 | 0.2 % | $ 5.7 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 25.0 | 2.19 % | $ 694 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 415.6 | 1.23 % | $ 12 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.56 | 1.53 % | $ 1.15 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 7.03 | -0.28 % | $ 293 M | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Soleno Therapeutics
SLNO
|
-431 M | $ 52.75 | 0.05 % | $ 2.68 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.26 | -0.31 % | $ 492 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 470.43 | 0.18 % | $ 177 B | USA |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Trinity Biotech plc
TRIB
|
10.6 M | $ 0.65 | -0.62 % | $ 61.9 M |  Irlanda |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 173.04 | 1.91 % | $ 8.58 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 60.29 | -1.07 % | $ 3.61 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 89.18 | 0.3 % | $ 11.2 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.98 | - | $ 8.76 M | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.59 | 0.52 % | $ 2.08 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.17 | 1.4 % | $ 4.98 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.46 | 1.33 % | $ 391 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 101.74 | -0.43 % | $ 8.39 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 264.08 | 0.11 % | $ 22 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 126.32 | 4.37 % | $ 5.91 B | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.35 | 0.72 % | $ 1.07 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.86 | 1.57 % | $ 450 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 205.24 | 0.73 % | $ 20.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 196.28 | 0.04 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
6.05 B | - | -0.91 % | $ 14.7 B | USA |